Surgical Device Maker's Shares Rise 7% on Q3 Earnings
Source: Streetwise Reports��(4/7/22)
Shares of AngioDynamics Inc. traded higher after the company reported Q3/22 financial results highlighting a 28.6% YoY increase in net Med Tech sales. More >

FDA Approves Bipolar and Schizophrenia Drug
Source: Streetwise Reports��(4/6/22)
BioXcel Therapeutics Inc. reported that the U.S. FDA has approved its IGALMI™ (dexmedetomidine) Sublingual Film for use in acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. More >

Imaging Co. Launches S. Korea Chip Production
Source: Streetwise Reports��(4/5/22)
Shares of Nano-X Imaging Ltd. traded 9% higher after the company reported it opened a new semiconductor chip fabrication plant in South Korea. The 12,000 sq. meter facility was commissioned to produce the firm's Nanox.SOURCE semiconductor chips for its novel digital Nanox.ARC 3D x-ray system. More >

Telemed Tech Co. Expands Markets and Revenue in 2022
Source: Streetwise Reports��(4/4/22)
A quarter of the way into the year, this global healthcare technology company is experiencing “phenomenal growth,” with “a lot of growth ahead of us” for the rest of this year. More >

Can We Make a Pill to End the Pandemic?
Source: Vision and Value��(4/4/22)
Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors. More >

Cannabis Infused Beverage Company Stock in 'Very Good Spot' to Purchase
Source: Clive Maund��(4/4/22)
Technical analyst Clive Maund explains why he rates this company a strong speculative buy. More >

Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial
Source: Streetwise Reports��(4/2/22)
NGM Biopharmaceuticals Inc. shares rose 14.75% after the company reported it dosed the first group of patients in its Phase 1/1b clinical trial of NGM831 for use in treating advanced solid tumors. More >

Chen's Top Picks for Q2 2022
Source: Streetwise Reports��(4/1/22)
Asset manager and contributing writer Chen Lin looks to the biotechnology and mining sectors for his top second quarter picks. More >

Biotech Co. Posts Notable PFS Gains in Ph. 3 Cancer Trial
Source: Streetwise Reports��(3/31/22)
Clovis Oncology Inc. shares traded 36% higher after the company reported that in the Phase 3 ATHENA-MONO clinical study its Rubraca® (Rucaparib) was shown to significantly improve progression-free survival in women diagnosed with ovarian cancer. More >

Biotech Firm's Shares Double on $6B Deal
Source: Streetwise Reports��(3/29/22)
Shares of IGM Biosciences Inc. traded 97% higher after the company reported FY/21 financial results and announced it entered into a collaborative partnership with Sanofi SA to develop six separate IgM antibody agonists for three oncology and three autoimmune/inflammation targets. More >

Shares Rise 10% After FDA Approval of Implantable Lens
Source: Streetwise Reports��(3/28/22)
STAAR Surgical Co. shares traded higher after the company reported that the U.S. FDA approved its EVO Visian® Implantable Collamer® Lenses to correct myopia (nearsightedness) and myopia with astigmatism. More >

Biotech Co. Posts Positive Data in Ph. 1/2 Kidney Cancer Trial
Source: Streetwise Reports��(3/23/22)
Shares of 4D Pharma Plc. traded 28% higher after the company reported positive interim results from its Phase 1/2 study of its MRx0518 in combination with Merck & Co.'s KEYTRUDA® (pembrolizumab) for use in treating renal cell carcinoma. More >

Biotech Co. Gets $2M Grant for Parkinson's Treatment
Source: Streetwise Reports��(3/22/22)
Shares of SQZ Biotechnologies Co. traded 17% higher after the company reported that it has been awarded a $2 million grant from the NIH to develop a new cell replacement therapy for use in treating Parkinson's disease. More >

Co. Awaits FDA Approval of Drug, Prepares for Launch
��(3/21/22)
The biopharma's executive team is managing both time and opex spending well, noted an Oppenheimer report. More >

Drug Co. Gets PDUFA Date for TKI
��(3/20/22)
"We expect poziotinib approval in late 2022 with sales of $21.9 million this year," noted an H.C. Wainwright & Co. report. More >

Produce Co. to Acquire Grower of Greens
��(3/19/22)
The transaction will increase the acquirer's returns and lower its operating risk, noted a ROTH Capital Partners report. More >

Pharma Co. Gains FDA Approval for Epilepsy Seizure Drug
Source: Streetwise Reports��(3/19/22)
Shares of Marinus Pharmaceuticals Inc. jumped 16.4% higher near the end of trading today after the company reported that the U.S. FDA granted approval for its ZTALMY® (ganaxolone) in treating a rare type of genetic epilepsy called CDKL5 deficiency disorder. More >

Catalyst Could Push Pharma to Break Out
Source: Michael Sheikh��(3/18/22)
This pharmaceutical company is trading well below its cash value and is on the cusp of a potentially significant catalyst, one analyst says. More >

Mental Health Co. Hosts Phase II Trials for LSD, Psilocybin
Source: Streetwise Reports��(3/16/22)
This mental health company is pioneering a unique, new treatment for mental health issues such as depression and PTSD in which psychedelics are administered by medical professionals in specialized clinics. More >

Biopharma Co. Enjoys Gains From Kidney Cancer Drug
Source: Streetwise Reports��(3/14/22)
Shares of this pharmaceuticals co. traded 22% higher after the company reported Q4/21 and FY/21 financial results that included a 17% sequential gain in net revenue from sales of its FOTIVDA® (tivozanib), which has been approved by the U.S. FDA for treating adults with relapsed or refractory advanced renal cell carcinoma (RCC). More >

License Revenues Kick in for Biopharma Co.
Source: Streetwise Reports��(3/12/22)
Shares of Clearside Biomedical Inc. traded 42% higher after the company reported Q4/21 and FY/21 financial results and provided an update regarding positive developments at the company including the receipt of over $20 million in milestone payments from its commercial development partner. More >

Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings
��(3/10/22)
An Oppenheimer report notes that this pharmaceutical company is working to expand the approved uses of its lead drug candidate, and numerous catalysts involving Empaveli are expected this year. More >

Biotech Firm Should Increase Sales by 20% This Year
��(3/10/22)
This immunotherapy company's outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front, noted an H.C. Wainwright & Co. report. More >

Medical Device Co. Changes Tack to Drive Topline Growth
��(3/9/22)
This medical device company is improving its laser ablation system and working toward U.S. approval for its use in a second application, noted a Ladenburg Thalmann report. More >

Pharma Co. Shares Get a Bang from FDA Orphan Drug Approval
Source: Streetwise Reports��(3/9/22)
Shares of C4 Therapeutics Inc. traded 16% higher after the biopharma company reported that the U.S. FDA granted Orphan Drug approval status for its CFT8634 for use in treating soft tissue sarcoma. More >